Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.

Target site selection must account for global and within host viral genetic diversity. Globally conserved target sites are good starting points for design, but multiplexing is essential for depleting quasispecies and preventing viral load rebound upon therapy cessation.